Financial Survey: Lisata Therapeutics (NASDAQ:LSTA) vs. Dyadic International (NASDAQ:DYAI)Defense World · Oct 15, 2026
Dyadic International Targets Commercial Traction as Life Sciences Products LaunchDefense World · Oct 5, 2026
Dyadic International (NASDAQ:DYAI) & Amylyx Pharmaceuticals (NASDAQ:AMLX) Critical ReviewDefense World · Oct 4, 2026
Dyadic International (NASDAQ:DYAI) Stock Breaks Below 50-Day Moving Average – Here’s WhyDefense World · Sep 30, 2026
Dyadic International, Inc. (DYAI) Presents at IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 TranscriptSeeking Alpha · Sep 15, 2026
Dyadic International (NASDAQ:DYAI) Stock Passes Below 50-Day Moving Average – Time to Sell?Defense World · Sep 15, 2026Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.04 | -$0.06 | Miss |
| May 13, 2026 | -$0.04 | -$0.05 | Miss |
| Mar 25, 2026 | -$0.03 | -$0.06 | Miss |
| Nov 12, 2025 | -$0.04 | -$0.06 | Miss |
| Aug 13, 2025 | -$0.06 | -$0.06 | Beat |
| May 14, 2025 | – | -$0.07 |